CD163 and neoplasm: On the basis of our findings, TWEAK expression in the metastatic tumor cells may be minimal, and its secretion in CRLMs may be mainly mediated by inflammatory cells, such as Th17 cells and CD163‐positive macrophages, in the tumor microenvironment.